Plasma transforming growth factor-β_1 levels in patients with erectile dysfunction
Plasma transforming growth factor-β_1 levels in patients with erectile dysfunction作者机构：Department of UrologyClinical Research CenterDepartment of UrologyDepartment of UrologyDepartment of UrologyNational Cancer InstituteDepartment of Urology Inha University School of Medicine Incheon Korea Yonsei University School of Medicine Seoul Korea National Institutes of Health Bethesda MD USA
出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)
年 卷 期：2004年第6卷第4期
页 面：349-353页
核心收录：
学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 100214[医学-肿瘤学] 10[医学]
主 题：erectile dysfunction transforming growth factor fibrosis diagnosis
摘 要：Aim: To evaluate the plasma TGF-β1 level in erectile dysfunction (ED) patients of various causes. Methods: Sixty-two patients with ED and 26 potent men were subjected to the study. Based on multidisciplinary work-ups, including medical history, physical examinations, blood tests with lipid profile and hormones, penile duplex Doppler ultrasonogram and neurophysiological tests, causes for ED were classified as psychogenic (n=15), neurogenic (n=16) and vasculogenic (n=31). The plasma TGF-β1 level was measured by the ELISA method. Results: The plasma TGF-β1 level was significantly increased in the ED group (6.7 ± 4.9 ng/mL), compared to the control (4.0±2.1 ng/mL) (P 0.01). In the ED groups, there was a significant increase in the vasculogenic group (9.0 ± 5.5 ng/mL), compared to the psychogenic (3.8 ± 1.8 ng/mL) and neurogenic groups (4.8 ± 3.2 ng/mL) (P0.01). Of the vascular risk factors, both the smoking (7.5 ± 4.7 ng/mL) and dyslipidemia groups (7.4 ± 4.4 ng/mL) showed significantly increased plasma TGF-β1 levels, compared to the non-smokers (5.5 ± 2.8 ng/mL), and those without dyslipidemia (4.8 ?2.8 ng/mL) (P0.05). Conclusion: Vascular risk factors are associated with an elevated plasma TGF-β1 level, which may contribute to cavernous fibrosis and ED.
维普期刊数据库
同方期刊数据库